What drugs should not be taken with axitinib/axitinib?

Axitinib/Axitinib is a targeted therapy drug mainly used to treat patients with advanced renal cell carcinoma, especially those whose disease has progressed despite other treatments. Its working mechanism mainly inhibits the vascular endothelial growth factor receptor (VEGFR) and other related tyrosine kinases, thereby reducing the blood supply of tumors and inhibiting the growth and spread of tumors. Axitinib has shown good efficacy in clinical trials and can significantly extend progression-free survival (PFS) and overall survival (OS), making it an important treatment option.

During medication, patients need to pay attention to drug interactions with axitinib, especially drug interactions related toCYP3A4/5 enzyme system. Axitinib is primarily metabolized by hepatic CYP3A4/5 enzymes; therefore, any drug that significantly affects these enzyme systems may alter axitinib plasma concentrations. Strong CYP3A4/5 inhibitors, such as ketoconazole, may increase the plasma exposure of axitinib, thereby increasing the risk of adverse reactions. Therefore, it is recommended to avoid coadministration of axitinib with these strong inhibitors. In addition, grapefruit and its juice may also increase axitinib plasma concentrations and should be avoided by patients during treatment.

On the other hand, strongCYP3A4/5 inducers such as rifampin, dexamethasone, phenytoin, etc. may reduce the plasma level of axitinib, leading to a decrease in its efficacy. Therefore, it is also very important to avoid combined use with these inducers. When taking concomitant medications, patients should choose drugs that do not inhibit or induce CYP3A4/5 to ensure the stability and effectiveness of treatment.

In conclusion, axitinib has a significant effect in the treatment of advanced renal cell carcinoma, but its safety and efficacy may be affected by interactions with other drugs. When using axitinib, patients need to follow the guidance of their physician, regularly monitor the plasma concentration of the drug, and carefully consult and evaluate possible drug interactions before use to ensure the best effect of treatment.

Reference materials:https://www.pfizermedicalinformation.com/inlyta/drug-interactions